

**DATA SHEET**  
**Hsa-miR-29a fluoresceinated oligo probe**

**Catalog No.**  
**HM29a-100**

**Description**  
One vial of 0.650 ml of probe in hybridization buffer

**Analyte Specific Reagent. Analytical and performance characteristics are not established.**

---

Doc. No. 932-HM29a-100

Rev. B

Date of release: 11-Aug-2020

**Description**

The Hsa-miR-29a probe has been designed from mature human miR-29a sequence. This fluoresceinated probe is provided in a hybridization buffer for localization of miRNA in FFPE tissue by *In Situ* hybridization.

**Specifications**

The Hsa-miR-29a identifies mature miR-29a sequences in formalin-fixed, paraffin-embedded human tissues and/or freshly prepared frozen tissues by *in situ* hybridization. This probe does not react with normal human mRNA or nuclear DNA present in tissues.

**Storage and Handling**

Store the reagent at 2-8 °C. Do not freeze. Do not use the reagent after expiration date on vial. The reagent must be brought to room temperature before use. (Important! The presence of precipitates induces background staining).

**Precautions:**

For professional use, the probe contains formamide. Formamide is classified as a teratogen. Pregnant workers should keep exposure to a minimum. Avoid inhalation, ingestion, and contact with unprotected skin. If skin contact occurs, wash thoroughly with soap and water. For more information, refer to the Material Safety Data Sheet, which is available upon request.

**Quality Control**

Each lot of this miRNA probe is tested by *In-Situ* hybridization for Quality Control purposes. Refer to the BioGenex Quality Control Testing Conditions table for additional information.

**References**

1. Wu Z, Huang X, Huang X, Zou Q, Guo Y (2013 Dec). The inhibitory role of Mir-29 in growth of breast cancer cells. J Exp Clin Cancer Res. 1;32:98.
2. Boon RA, Seeger T, Heydt S, Fischer A, Hergenreider E, Horrevoets AJ, Vinciguerra M, Rosenthal N, Sciacca S, Pilato M, van Heijningen P, Essers J, Brandes RP, Zeiher AM, Dimmeler S (2011). MicroRNA-29 in aortic dilation: implications for aneurysm formation. Circ Res 109: 1115– 1119, 2011.

**BioGenex Quality Control Testing Conditions**

<b>Parameter</b>	<b>Conditions used</b>
Control Tissue	Transitional Cell Carcinoma (FB-HM29A)
Tissue Type	Formalin-fixed, paraffin-embedded cancer tissues